<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">PAR</journal-id><journal-title-group><journal-title>Proceedings of Anticancer Research</journal-title></journal-title-group><issn>2208-3545</issn><eissn>2208-3553</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/par.v9i6.13003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Mechanism of Hedysarum Multijugum Maxim. in Treatment of Bladder Cancer Based on Network Pharmacology and Molecular Docking Technology</title><url>https://artdesignp.com/journal/PAR/9/6/10.26689/par.v9i6.13003</url><author>TianHong,ZhangYunchen,HuYang,XuanChong Yun,SunLiquan,GuHao</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>6</issue><history><date date-type="pub"><published-time>2025-12-10</published-time></date></history><abstract>To investigate the targets and mechanism of Hedysarum Multijugum Maxim (HMM) in treatment of bladder cancer (BC). Based on Traditional Chinese Medicine Systems Pharmacology (TCMSP) and gene databases, active substances and potential targets of HMM were screened, and the HMM-active substances-targets-BC (HATB) regulatory network and PPI network were constructed. Hub targets were screened by Cytoscape. The main active substances and Hub targets were molecularly docked with AutoDock and visualized by PyMOL. 12 Hub targets were screened. Molecular docking showed that active substances mainly acted on MAPK14, MAPK1 and CCND1. The bindings of calycosin to MAPK14, formononetin to MAPK14, and calycosin to CCND1 were stable.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Dobruch J, Oszczudłowski M, 2021, Bladder Cancer: Current Challenges and Future Directions. Medicina, 57(8): 749.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Huang C, Zheng C, Li Y, et al., 2014, Systems Pharmacology in Drug Discovery and Therapeutic Insight for Herbal Medicines. Briefings in Bioinformatics, 15(5): 710–733.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Zhu Y, Li G, Sun W, et al., 2023, Huangqi (Radix Astragali) Inhibits the Migration and Invasion of Bladder Cancer Through the Janus Kinase/Signal Transduction and Transcription Activation Factor Signaling Pathway Inhibited by MicroRNA-133A. Anhui Medicine, 27(1): 55–59 + 217.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Tongfu K, Yin X, Zhang Z, et al., 2023, Inhibitory Effect of Astragaloside Ⅱ on the Growth of Renal Clear Cell Carcinoma Cell and Its Mechanism. Journal of Shandong University (Medical Edition), 61(1): 10–16.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Liu F, Pan Q, Wang L, et al., 2020, Bioinformatic and Experimental Findings to Indicate Anti-Cancer Targets and Mechanisms of Calycosin Against Nasopharyngeal Carcinoma. Research Square, 1–14.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Zhang X, Liang M, Huang W, et al., 2015, Effects of Formononetin on Apoptosis of Bladder Cancer Cells. China Public Health, 31(3): 314–317.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Kudaravalli S, Hollander P, Mani S, 2022, Role of p38 MAP Kinase in Cancer Stem Cells and Metastasis. Oncogene, 41(23): 3177–3185.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Yuan L, 2011, Study on CCND1 Gene Polymorphism and Genetic Susceptibility of Bladder Cancer in China Han Population. Nanjing Medical University, 2011.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Chen X, Wang P, Wang S, et al., 2019, CIZ1 Knockdown Suppresses the Proliferation of Bladder Cancer Cells by Inducing Apoptosis. Gene, 719: 143946.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Watters A, Latif Z, Forsyth A, et al., 2002, Genetic Aberrations of c-myc and CCND1 in the Development of Invasive Bladder Cancer. British Journal of Cancer, 87(6): 654–658.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
